ES2904709T3 - Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas - Google Patents
Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas Download PDFInfo
- Publication number
- ES2904709T3 ES2904709T3 ES20165165T ES20165165T ES2904709T3 ES 2904709 T3 ES2904709 T3 ES 2904709T3 ES 20165165 T ES20165165 T ES 20165165T ES 20165165 T ES20165165 T ES 20165165T ES 2904709 T3 ES2904709 T3 ES 2904709T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- amino acid
- antibody
- resp
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13168941 | 2013-05-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2904709T3 true ES2904709T3 (es) | 2022-04-05 |
Family
ID=48485015
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20165165T Active ES2904709T3 (es) | 2013-05-23 | 2014-05-22 | Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas |
| ES14729463T Active ES2784616T3 (es) | 2013-05-23 | 2014-05-22 | Moléculas de unión que se unen al factor C2 del complemento y usos de las mismas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14729463T Active ES2784616T3 (es) | 2013-05-23 | 2014-05-22 | Moléculas de unión que se unen al factor C2 del complemento y usos de las mismas |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9944717B2 (enExample) |
| EP (2) | EP3725803B1 (enExample) |
| JP (3) | JP2016520313A (enExample) |
| CN (1) | CN105492461B (enExample) |
| AU (1) | AU2014269193C1 (enExample) |
| CA (1) | CA2913318C (enExample) |
| DK (2) | DK3725803T3 (enExample) |
| ES (2) | ES2904709T3 (enExample) |
| HU (2) | HUE049769T2 (enExample) |
| LT (2) | LT2999714T (enExample) |
| MX (1) | MX366046B (enExample) |
| PL (2) | PL3725803T3 (enExample) |
| PT (2) | PT3725803T (enExample) |
| WO (1) | WO2014189378A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS63212B1 (sr) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| DK3725803T3 (da) * | 2013-05-23 | 2022-03-07 | Broteio Pharma B V | Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf |
| EP3525583B8 (en) | 2016-10-12 | 2025-09-10 | Bioverativ USA Inc. | Anti-c1s antibodies and methods of use thereof |
| FI3893924T3 (fi) * | 2018-12-13 | 2024-10-04 | argenx BV | Ihmisen komplementtitekijän C2B vasta-aineita sekä niiden käyttötapoja |
| GB2584105B (en) | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
| US20220332804A1 (en) * | 2019-08-12 | 2022-10-20 | Csl Innovation Pty Ltd. | Complement C2 Binding Proteins and Uses Thereof |
| EP4469475A1 (en) * | 2022-01-29 | 2024-12-04 | Kira Pharmaceuticals (Suzhou) Ltd. | Anti-c2 antibodies and uses thereof |
| GB202407051D0 (en) | 2024-05-17 | 2024-07-03 | argenx BV | Methods of treating osteoarthritis pain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| ATE435873T1 (de) | 2000-03-23 | 2009-07-15 | Genentech Inc | Anti-c2/c2a inhibitoren zur komplement aktivierung |
| DK3725803T3 (da) | 2013-05-23 | 2022-03-07 | Broteio Pharma B V | Bindingsmolekyler som binder human komplementfaktor C2b, og anvendelser deraf |
-
2014
- 2014-05-22 DK DK20165165.0T patent/DK3725803T3/da active
- 2014-05-22 HU HUE14729463A patent/HUE049769T2/hu unknown
- 2014-05-22 PT PT201651650T patent/PT3725803T/pt unknown
- 2014-05-22 CN CN201480042146.0A patent/CN105492461B/zh active Active
- 2014-05-22 PL PL20165165T patent/PL3725803T3/pl unknown
- 2014-05-22 HU HUE20165165A patent/HUE057858T2/hu unknown
- 2014-05-22 AU AU2014269193A patent/AU2014269193C1/en active Active
- 2014-05-22 EP EP20165165.0A patent/EP3725803B1/en active Active
- 2014-05-22 PL PL14729463T patent/PL2999714T3/pl unknown
- 2014-05-22 LT LTEP14729463.1T patent/LT2999714T/lt unknown
- 2014-05-22 PT PT147294631T patent/PT2999714T/pt unknown
- 2014-05-22 EP EP14729463.1A patent/EP2999714B1/en active Active
- 2014-05-22 CA CA2913318A patent/CA2913318C/en active Active
- 2014-05-22 DK DK14729463.1T patent/DK2999714T3/da active
- 2014-05-22 ES ES20165165T patent/ES2904709T3/es active Active
- 2014-05-22 JP JP2016515304A patent/JP2016520313A/ja active Pending
- 2014-05-22 MX MX2015016120A patent/MX366046B/es active IP Right Grant
- 2014-05-22 US US14/892,850 patent/US9944717B2/en active Active
- 2014-05-22 ES ES14729463T patent/ES2784616T3/es active Active
- 2014-05-22 WO PCT/NL2014/050327 patent/WO2014189378A1/en not_active Ceased
- 2014-05-22 LT LTEP20165165.0T patent/LT3725803T/lt unknown
-
2018
- 2018-02-23 US US15/903,810 patent/US10717785B2/en active Active
-
2019
- 2019-08-13 JP JP2019148550A patent/JP7163254B2/ja active Active
-
2022
- 2022-10-19 JP JP2022167816A patent/JP7414929B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2904709T3 (es) | Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas | |
| US11421031B2 (en) | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof | |
| ES2795667T3 (es) | Composiciones para inhibir la activación del complemento dependiente de MASP-2 | |
| ES3009440T3 (en) | Anti human annexin a1 antibody | |
| TW201741340A (zh) | Cd47抗體及使用其之方法 | |
| TW201805304A (zh) | 用於治療各種疾病和病症的抑制masp-3的組合物和方法 | |
| JP2024062992A (ja) | Ｃｄ２２に結合する重鎖抗体 | |
| JP2014530188A (ja) | Ｐｃｓｋ９に対する抗体およびその使用 | |
| TW201302794A (zh) | 人類組織因子抗體及其用途 | |
| CN104603150A (zh) | 与CH4和CεmX结构域之间的连接处结合的抗mIgE抗体 | |
| JP7754841B2 (ja) | ヒト化抗ヒトｃｄ８９抗体及びその使用 | |
| HK1223385B (zh) | 结合人类补体因子c2的结合分子及其应用 | |
| RU2797348C2 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 | |
| EA045291B1 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с cd22 | |
| TW201335184A (zh) | 人類組織因子抗體及其用途 |